Charles Schwab Investment Management Inc Graphite Bio, Inc. Transaction History

Charles Schwab Investment Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$2.47 - $3.38 $158,191 - $216,472	64,045 Added 361.02%	81,785 $212,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $50,026 - $75,217	17,740 New	17,740 $57,000
Q2 2022 Aug 15, 2022	SELL	$2.14 - $5.23 $153,444 - $375,006	-71,703 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$5.1 - $13.06 $148,364 - $379,928	29,091 Added 68.27%	71,703 $366,000
Q4 2021 Feb 11, 2022	BUY	$8.41 - $16.71 $23,674 - $47,038	2,815 Added 7.07%	42,612 $530,000
Q3 2021 Nov 16, 2021	BUY	$15.81 - $28.39 $629,190 - $1.13 Million	39,797 New	39,797 $653,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.